Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Home
Hostname: page-component-684899dbb8-4btjb Total loading time: 0.376 Render date: 2022-05-26T08:32:32.914Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "useRatesEcommerce": false, "useNewApi": true }
  • English
Psychological Medicine Psychological Medicine

Article contents

Is cognitive impairment associated with antipsychotic dose and anticholinergic equivalent loads in first-episode psychosis?

Published online by Cambridge University Press:  14 January 2018

Alejandro Ballesteros ,
Ana M. Sánchez-Torres ,
Jose M. López-Ilundain ,
Bibiana Cabrera ,
Antonio Lobo ,
Ana M. González-Pinto ,
Covadonga Díaz-Caneja ,
Iluminada Corripio ,
Eduard Vieta  and
Elena de la Serna
...Show all authors
Alejandro Ballesteros
Affiliation:
Estella Mental Health Center, Dirección de Salud Mental, Pamplona, Navarra, Spain IdiSNA, Navarra Institute for Health Research, Pamplona, Spain
Ana M. Sánchez-Torres
Affiliation:
IdiSNA, Navarra Institute for Health Research, Pamplona, Spain Department of Psychiatry, Complejo Hospitalario of Navarra, Pamplona, Spain
Jose M. López-Ilundain
Affiliation:
IdiSNA, Navarra Institute for Health Research, Pamplona, Spain Department of Psychiatry, Complejo Hospitalario of Navarra, Pamplona, Spain
Bibiana Cabrera
Affiliation:
Barcelona Clínic Schizophrenia Unit, Neuroscience Institute, Hospital Clínic de Barcelona, Barcelona, Spain Network Centre for Biomedical Research in Mental Health (CIBERSAM), Madrid, Spain
Antonio Lobo
Affiliation:
Department of Medicine and Psychiatry, University of Zaragoza. Aragon Institute for Health Research (IIS Aragon), Zaragoza, Spain
Ana M. González-Pinto
Affiliation:
Network Centre for Biomedical Research in Mental Health (CIBERSAM), Madrid, Spain BIOARABA Health Research Institute, OSI Araba. University Hospital, Vitoria, Spain University of the Basque Country, Vitoria, Spain
Covadonga Díaz-Caneja
Affiliation:
Network Centre for Biomedical Research in Mental Health (CIBERSAM), Madrid, Spain Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, IiSGM, School of Medicine, Universidad Complutense, Madrid, Spain
Iluminada Corripio
Affiliation:
Network Centre for Biomedical Research in Mental Health (CIBERSAM), Madrid, Spain Department of Psychiatry, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
Eduard Vieta
Affiliation:
Network Centre for Biomedical Research in Mental Health (CIBERSAM), Madrid, Spain Department of Psychiatry and Psychology, Clinical Institute for the Neurosciences, Hospital Clinic of Barcelona, Catalonia, Spain August Pi i Sunyer Institute for Biomedical Research (IDIBAPS), Barcelona, Catalonia, Spain Department of Psychiatry and Clinical Psychology, University of Barcelona, Catalonia, Spain Department of Psychiatry and Clinical Psychobiology, University of Barcelona, IDIBAPS, Barcelona, Spain
Elena de la Serna
Affiliation:
Network Centre for Biomedical Research in Mental Health (CIBERSAM), Madrid, Spain Child and Adolescent Psychiatry and Psychology Department, Department of Medicine, 2014SGR489, Institute Clinic of Neurosciences, Hospital Clinic of Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain
Julio Bobes
Affiliation:
Network Centre for Biomedical Research in Mental Health (CIBERSAM), Madrid, Spain Psychiatry Department, University of Oviedo, Oviedo, Spain Institute of Neurosciences of the Principality of Asturias, INEUROPA, Oviedo, Spain
Judith Usall
Affiliation:
Network Centre for Biomedical Research in Mental Health (CIBERSAM), Madrid, Spain Parc Sanitari Sant Joan de Déu, Sant Boi de Llobregat Barcelona, Spain
Fernando Contreras
Affiliation:
Network Centre for Biomedical Research in Mental Health (CIBERSAM), Madrid, Spain Psychiatry Department, Bellvitge University Hospital-IDIBELL Department of Clinical Sciences, School of Medicine, University of Barcelona, Barcelona, Spain
Ruth Lorente-Omeñaca
Affiliation:
IdiSNA, Navarra Institute for Health Research, Pamplona, Spain Department of Psychiatry, Complejo Hospitalario of Navarra, Pamplona, Spain
Gisela Mezquida
Affiliation:
Barcelona Clínic Schizophrenia Unit, Neuroscience Institute, Hospital Clínic de Barcelona, Barcelona, Spain Network Centre for Biomedical Research in Mental Health (CIBERSAM), Madrid, Spain
Miguel Bernardo
Affiliation:
Barcelona Clínic Schizophrenia Unit, Neuroscience Institute, Hospital Clínic de Barcelona, Barcelona, Spain Network Centre for Biomedical Research in Mental Health (CIBERSAM), Madrid, Spain Department of Psychiatry and Clinical Psychobiology, University of Barcelona, IDIBAPS, Barcelona, Spain
Manuel J. Cuesta*
Affiliation:
IdiSNA, Navarra Institute for Health Research, Pamplona, Spain Department of Psychiatry, Complejo Hospitalario of Navarra, Pamplona, Spain
PEPs Group
Affiliation:
Barcelona Clínic Schizophrenia Unit, Neuroscience Institute, Hospital Clínic de Barcelona, Barcelona, Spain Network Centre for Biomedical Research in Mental Health (CIBERSAM), Madrid, Spain BIOARABA Health Research Institute, OSI Araba. University Hospital, Vitoria, Spain University of the Basque Country, Vitoria, Spain Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, IiSGM, School of Medicine, Universidad Complutense, Madrid, Spain Department of Psychiatry, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, IiSGM, Madrid, Spain Department of Psychiatry, Hospital Clínico Universitario, Instituto de Investigación Sanitaria Aragón (IIS Aragón), Zaragoza, Spain Quiron Hospital, Instituto de Investigación Sanitaria Aragón (IIS Aragón), Zaragoza, Spain First Episode Psychiatric Unit, Valencia Clinic Hospital, INCLIVA, Valencia, Spain Hospital del Mar Medical Research Institute (IMIM), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain Department of Neurosciences, University of the Basque Country (UPV/EHU), BioCruces Health Research Institute, Baracaldo, Spain Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain Sant Joan de Déu Research Foundation, Esplugues de Llobregat, Barcelona, Spain Faculty of Psychology, University of Barcelona, Spain Hospital Sant Joan de Déu, Barcelona, Spain FIDMAG Hermanas Hospitalarias Research Foundation, Barcelona, Spain Neuroscience Research Australia, Sydney, NSW, Australia Australia School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia Australia ARC Centre of Excellence in Cognition and its Disorders, Sydney, NSW, Australia Department of Psychiatry, Hospital Universitario Ramón y Cajal, IRYCIS, Universidad de Alcalá, Madrid, Spain Service of Psychiatry, La Fe University and Polytechnic Hospital, Valencia, Spain Department of Medicine, University of Valencia, Valencia, Spain
*
Author for correspondence: Manuel J. Cuesta, E-mail: mcuestaz@cfnavarra.es
Get access Rights & Permissions[Opens in a new window]

Abstract

Background

Cognitive deficits are a core feature of early stages in schizophrenia. However, the extent to which antipsychotic (AP) have a deleterious effect on cognitive performance remains under debate. We aim to investigate whether anticholinergic loadings and dose of AP drugs in first episode of psychosis (FEP) in advanced phase of remission are associated with cognitive impairment and the differences between premorbid intellectual quotient (IQ) subgroups.

Methods

Two hundred and sixty-six patients participated. The primary outcomes were cognitive dimensions, dopaminergic/anticholinergic load of AP [in chlorpromazine equivalents (Eq-CPZ) and the Anticholinergic Risk Scale (ARS), respectively].

Results

Impairments in processing speed, verbal memory and global cognition were significantly associated with high Eq-CPZ and verbal impairment with high ARS score. Moreover, this effect was higher in the low IQ subgroup.

Conclusions

Clinicians should be aware of the potential cognitive impairment associated with AP in advanced remission FEP, particularly in lower premorbid IQ patients.

Keywords

Anticholinergicantipsychoticscognitionfirst episode psychosispremorbid intellectual quotient.
Type
Original Articles
Information
Psychological Medicine , Volume 48 , Issue 13 , October 2018 , pp. 2247 - 2256
Copyright
Copyright © Cambridge University Press 2018 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

†

The authors of the PEPs Group who participated in this manuscript are: Miquel Bioque4,5, Silvia Amoretti4,5, Mara Parellada5,9, Raquel Vicente5,21, Anna Alonso5,10, Mireia Rabella5,10, Itxaso González-Ortega5,7,8, Patricia Vega5,7,8, Julio Arbej22, Nicolás Fayed23, Julio Sanjuan5,24, Esther Lorente-Rovira5,24, Daniel Bergé5,25, Antoni Bulbena5,25, Diego Hidalgo-Mazzei5,11,12,13, Marina Garriga5,11,12,13, Immaculada Baeza5,15, Josefina Castro-Fornieles5,15, Àuria Albacete5,19,20, Jose Manuel Menchón5,19,20, Mª Paz García-Portilla5,16,17, Leticia García-Álvarez5,16,17, Miguel Gutiérrrez5,7, Aranzazu Zabala5,26, Roberto Rodriguez-Jimenez5,27, Isabel Morales-Muñoz27, Anna Butjosa5,18,28,29, Marta Pardo-Gallego30, Salvador Sarró5,31, Ramón Landín-Moreno32,33,34, Ángela Ibáñez5,35, Lucía Moreno-Izco2,3 and Vicente Balanzá-Martínez5,36,37.

References

Abbott, C, Juárez, M, White, T, Gollub, RL, Pearlson, GD, Bustillo, J et al. (2011) Antipsychotic dose and diminished neural modulation: a multi-site fMRI study. Progress in Neuro-Psychopharmacology and Biological Psychiatry 35, 473–482.CrossRefGoogle ScholarPubMed
Alvarez-Jimenez, M, O'Donoghue, B, Thompson, A, Gleeson, JF, Bendall, S, Gonzalez-Blanch, C et al. (2016) Beyond clinical remission in first episode psychosis: thoughts on antipsychotic maintenance vs. guided discontinuation in the functional recovery era. CNS Drugs 30, 357–368.CrossRefGoogle ScholarPubMed
Allain, H, Tessier, C, Bentué-Ferrer, D, Tarral, A, Le Breton, S, Gandon, M et al. (2003) Effects of risperidone on psychometric and cognitive functions in healthy elderly volunteers. Psychopharmacology 165, 419–429.CrossRefGoogle ScholarPubMed
American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). Washington: American Psychiatric Association.Google Scholar
Amoretti, S, Bernardo, M, Bonnin, CM, Bioque, M, Cabrera, B, Mezquida, G et al. (2016) The impact of cognitive reserve in the outcome of first-episode psychoses: 2-year follow-up study. European Neuropsychopharmacology 26, 1638–1648.CrossRefGoogle ScholarPubMed
Andreou, C, Roesch-Ely, D, Veckenstedt, R, Bohn, F, Aghotor, J, Köther, U et al. (2013) Predictors of early stable symptomatic remission after an exacerbation of schizophrenia: the significance of symptoms, neuropsychological performance and cognitive biases. Psychiatry Research 210, 729–734.CrossRefGoogle ScholarPubMed
Artaloytia, JF, Arango, C, Lahti, A, Sanz, J, Pascual, A, Cubero, P et al. (2006) Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers. American Journal of Psychiatry 163, 488–493.CrossRefGoogle ScholarPubMed
Baitz, HA, Thornton, AE, Procyshyn, RM, Smith, GN, MacEwan, GW, Kopala, LC et al. (2012) Antipsychotic medications: linking receptor antagonism to neuropsychological functioning in first episode psychosis. Journal of the International Neuropsychological Society 18, 717–727.CrossRefGoogle ScholarPubMed
Barnett, JH, Salmond, CH, Jones, PB and Sahakian, BJ (2006) Cognitive reserve in neuropsychiatry. Psychological Medicine 36, 1053–1064.CrossRefGoogle ScholarPubMed
Benedet, MJ and Alejandre, MA (1998) Test de Aprendizaje Verbal España-Complutense. Madrid: TEA Ediciones.Google Scholar
Bernardo, M, Bioque, M, Cabrera, B, Lobo, A, González-Pinto, A, Pina, L et al. (2017) Modelling gene-environment interaction in first episodes of psychosis. Schizophrenia Research 189, 181–189.CrossRefGoogle Scholar
Bernardo, M, Bioque, M, Parellada, M, Saiz Ruiz, J, Cuesta, MJ, Llerena, A et al. (2013) Assessing clinical and functional outcomes in a gene-environment interaction study in first episode of psychosis (PEPs). Revista de Psiquiatria y Salud Mental 6, 4–16.CrossRefGoogle Scholar
Cohen, JD, Barch, DM, Carter, C and Servan-Schreiber, D (1999) Context-processing deficits in schizophrenia: converging evidence from three theoretically motivated cognitive tasks. Journal of Abnormal Psychology 108, 120–133.CrossRefGoogle ScholarPubMed
Conners, CK (2000) Continuous Performance Test-II. Toronto: MHS.Google Scholar
Cuesta, MJ, García de Jalon, E, Campos, MS and Peralta, V (2009) Cognitive effectiveness of olanzapine and risperidone in first-episode psychosis. British Journal of Psychiatry 194, 439–445.CrossRefGoogle ScholarPubMed
Cuesta, MJ, Peralta, V and Zarzuela, A (2001) Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study. Schizophrenia Research 48, 17–28.CrossRefGoogle ScholarPubMed
Cuesta, MJ, Sánchez-Torres, AM, Cabrera, B, Bioque, M, Merchán-Naranjo, J, Corripio, I et al. (2015) Premorbid adjustment and clinical correlates of cognitive impairment in first-episode psychosis. The PEPsCog Study. Schizophrenia Research 164, 65–73.CrossRefGoogle ScholarPubMed
Choi, KH, Wykes, T and Kurtz, MM (2013) Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: meta-analytical investigation of efficacy. British Journal of Psychiatry 203, 172–178.CrossRefGoogle Scholar
Chung, YC, Park, TW, Yang, JC, Huang, GB, Zhao, T, Oh, KY et al. (2012) Cognitive effects of a single dose of atypical antipsychotics in healthy volunteers compared with placebo or haloperidol. Journal of Clinical Psychopharmacology 32, 778–786.CrossRefGoogle ScholarPubMed
Danivas, V and Venkatasubramanian, G (2013) Current perspectives on chlorpromazine equivalents: comparing apples and oranges! Indian Journal of Psychiatry 55, 207–208.Google ScholarPubMed
Davidson, M, Galderisi, S, Weiser, M, Werbeloff, N, Fleischhacker, WW, Keefe, RS et al. (2009) Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). American Journal of Psychiatry 166, 675–682.CrossRefGoogle Scholar
de la Serna, E, Andrés-Perpiñá, S, Puig, O, Baeza, I, Bombin, I, Bartrés-Faz, D et al. (2013) Cognitive reserve as a predictor of two year neuropsychological performance in early onset first-episode schizophrenia. Schizophrenia Research 143, 125–131.CrossRefGoogle ScholarPubMed
Dias, VV, Balanzá-Martinez, V, Soeiro-de-Souza, MG, Moreno, RA, Figueira, ML, Machado-Vieira, R et al. (2012) Pharmacological approaches in bipolar disorders and the impact on cognition: a critical overview. Acta Psychiatrica Scandinavica 126, 315–331.CrossRefGoogle ScholarPubMed
Elie, D, Poirier, M, Chianetta, J, Durand, M, Grégoire, C and Grignon, S (2010) Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder. Journal of Psychopharmacology 24, 1037–1044.CrossRefGoogle ScholarPubMed
Eum, S, Hill, SK, Rubin, LH, Carnahan, RM, Reilly, JL, Ivleva, EI et al. (2017) Cognitive burden of anticholinergic medications in psychotic disorders. Schizophrenia Research 190, 129–135.CrossRefGoogle ScholarPubMed
Faber, G, Smid, HG, Van Gool, AR, Wiersma, D and Van Den Bosch, RJ (2012) The effects of guided discontinuation of antipsychotics on neurocognition in first onset psychosis. European Psychiatry 27, 275–280.CrossRefGoogle ScholarPubMed
Gardner, DM, Murphy, AL, O'Donnell, H, Centorrino, F and Baldessarini, RJ (2010) International consensus study of antipsychotic dosing. American Journal of Psychiatry 167, 686–693.CrossRefGoogle ScholarPubMed
Golden, CJ (1978) Stroop Color and Word Test. A Manual for Clinical and Experimental Uses. Wood Dale, IL: Stoelting Co.Google Scholar
González-Blanch, C, Rodríguez-Sánchez, JM, Pérez-Iglesias, R, Pardo-García, G, Martínez-García, O, Vázquez-Barquero, JL et al. (2010) First-episode schizophrenia patients neuropsychologically within the normal limits: evidence of deterioration in speed of processing. Schizophrenia Research 119, 18–26.CrossRefGoogle ScholarPubMed
Green, MF and Nuechterlein, KH (2004) The MATRICS initiative: developing a consensus cognitive battery for clinical trials. Schizophrenia Research 72, 1–3.CrossRefGoogle ScholarPubMed
Green, MF, Nuechterlein, KH, Gold, JM, Barch, DM, Cohen, J, Essock, S et al. (2004) Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biological Psychiatry 56, 301–307.CrossRefGoogle ScholarPubMed
Gur, RE, Calkins, ME, Gur, RC, Horan, WP, Nuechterlein, KH, Seidman, LJ et al. (2007) The consortium on the genetics of schizophrenia: neurocognitive endophenotypes. Schizophrenia Bulletin 33, 49–68.CrossRefGoogle Scholar
Gutiérrez-Galve, L, Chu, EM, Leeson, VC, Price, G, Barnes, TR, Joyce, EM et al. (2015) A longitudinal study of cortical changes and their cognitive correlates in patients followed up after first-episode psychosis. Psychological Medicine 45, 205–216.CrossRefGoogle ScholarPubMed
Harvey, PD and Keefe, RS (2001) Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. American Journal of Psychiatry 158, 176–184.CrossRefGoogle ScholarPubMed
Harvey, PD, Rabinowitz, J, Eerdekens, M and Davidson, M (2005) Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. American Journal of Psychiatry 162, 1888–1895.CrossRefGoogle Scholar
He, Z, Deng, W, Li, M, Chen, Z, Jiang, L, Wang, Q et al. (2013) Aberrant intrinsic brain activity and cognitive deficit in first-episode treatment-naive patients with schizophrenia. Psychological Medicine 43, 769–780.CrossRefGoogle ScholarPubMed
Heaton, R, Chelune, G, Talley, J, Kay, G and Curtiss, G (1993) Wisconsin Card Sorting Test. Odessa, FL: Psychological Assessment Resources.Google Scholar
Karson, C, Duffy, RA, Eramo, A, Nylander, AG and Offord, SJ (2016) Long-term outcomes of antipsychotic treatment in patients with first-episode schizophrenia: a systematic review. Neuropsychiatric Disease and Treatment 12, 57–67.CrossRefGoogle ScholarPubMed
Kawai, N, Yamakawa, Y, Baba, A, Nemoto, K, Tachikawa, H, Hori, T et al. (2006) High-dose of multiple antipsychotics and cognitive function in schizophrenia: the effect of dose-reduction. Progress in Neuro-Psychopharmacology and Biological Psychiatry 30, 1009–1014.CrossRefGoogle ScholarPubMed
Kay, SR, Fiszbein, A and Opler, LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13, 261–276.CrossRefGoogle Scholar
Keefe, RS, Bilder, RM, Davis, SM, Harvey, PD, Palmer, BW, Gold, JM et al. (2007a) Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Archives of General Psychiatry 64, 633–647.CrossRefGoogle Scholar
Keefe, RS, Seidman, LJ, Christensen, BK, Hamer, RM, Sharma, T, Sitskoorn, MM et al. (2004) Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. American Journal of Psychiatry 161, 985–995.CrossRefGoogle ScholarPubMed
Keefe, RS, Seidman, LJ, Christensen, BK, Hamer, RM, Sharma, T, Sitskoorn, MM et al. (2006) Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis. Biological Psychiatry 59, 97–105.CrossRefGoogle ScholarPubMed
Keefe, RS, Sweeney, JA, Gu, H, Hamer, RM, Perkins, DO, McEvoy, JP et al. (2007b) Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. American Journal of Psychiatry 164, 1061–1071.CrossRefGoogle Scholar
Killackey, E, Jackson, HJ and McGorry, PD (2008) Vocational intervention in first-episode psychosis: individual placement and support v. treatment as usual. British Journal of Psychiatry 193, 114–120.CrossRefGoogle ScholarPubMed
Koenen, KC, Moffitt, TE, Roberts, AL, Martin, LT, Kubzansky, L, Harrington, H et al. (2009) Childhood IQ and adult mental disorders: a test of the cognitive reserve hypothesis. American Journal of Psychiatry 166, 50–57.CrossRefGoogle ScholarPubMed
Konig, P, Benzer, MK and Fritzche, H (1991) SPECT technique for visualization of cerebral dopamine D2 receptors. American Journal of Psychiatry 148, 1607–1608.Google ScholarPubMed
Landi, F, Dell'Aquila, G, Collamati, A, Martone, AM, Zuliani, G, Gasperini, B et al. (2014) Anticholinergic drug use and negative outcomes among the frail elderly population living in a nursing home. Journal of the Americans Medical Directors Association 15, 825–829.CrossRefGoogle Scholar
Lane, CJ, Ngan, ET, Yatham, LN, Ruth, TJ and Liddle, PF (2004) Immediate effects of risperidone on cerebral activity in healthy subjects: a comparison with subjects with first-episode schizophrenia. Journal of Psychiatry and Neuroscience 29, 30–37.Google ScholarPubMed
Leeson, VC, Sharma, P, Harrison, M, Ron, MA, Barnes, TR and Joyce, EM (2011) IQ trajectory, cognitive reserve, and clinical outcome following a first episode of psychosis: a 3-year longitudinal study. Schizophrenia Bulletin 37, 768–777.CrossRefGoogle ScholarPubMed
Leucht, S, Samara, M, Heres, S and Davis, JM (2016) Dose equivalents for antipsychotic drugs: the DDD method. Schizophrenia Bulletin 42(Suppl. 1), S90–S94.CrossRefGoogle ScholarPubMed
Loonstra, AS, Tarlow, AR and Sellers, AH (2001) COWAT metanorms across age, education, and gender. Applied Neuropsychology 8, 161–166.CrossRefGoogle ScholarPubMed
Mangoni, AA, Kim, S, Hakendorf, P, Mayner, L and Woodman, RJ (2016) Heat waves, drugs with anticholinergic effects, and outcomes in older hospitalized adults. Journal of the American Geriatrics Society 64, 1091–1096.CrossRefGoogle ScholarPubMed
Mayer, JD, Salovey, P and Caruso, DR (2009) Mayer-Salovey-Caruso Emotional Intelligence Test (Spanish Version). Madrid: TEA Ediciones.Google Scholar
Mayoral-van Son, J, de la Foz, VO, Martinez-Garcia, O, Moreno, T, Parrilla-Escobar, M, Valdizan, EM et al. (2016) Clinical outcome after antipsychotic treatment discontinuation in functionally recovered first-episode nonaffective psychosis individuals: a 3-year naturalistic follow-up study. Journal of Clinical Psychiatry 77, 492–500.CrossRefGoogle ScholarPubMed
McGaughy, J, Dalley, JW, Morrison, CH, Everitt, BJ and Robbins, TW (2002) Selective behavioral and neurochemical effects of cholinergic lesions produced by intrabasalis infusions of 192 IgG-saporin on attentional performance in a five-choice serial reaction time task. Journal of Neuroscience 22, 1905–1913.CrossRefGoogle Scholar
Minzenberg, MJ, Poole, JH, Benton, C and Vinogradov, S (2004) Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. American Journal of Psychiatry 161, 116–124.CrossRefGoogle Scholar
Mizrahi, R, Agid, O, Borlido, C, Suridjan, I, Rusjan, P, Houle, S et al. (2011) Effects of antipsychotics on D3 receptors: a clinical PET study in first episode antipsychotic naive patients with schizophrenia using [11C]-(+)-PHNO. Schizophrenia Research 131, 63–68.CrossRefGoogle Scholar
Murray, RM, Quattrone, D, Natesan, S, van Os, J, Nordentoft, M, Howes, O et al. (2016) Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics? British Journal of Psychiatry 209, 361–365.CrossRefGoogle ScholarPubMed
Nakazawa, K, Zsiros, V, Jiang, Z, Nakao, K, Kolata, S, Zhang, S et al. (2012) GABAergic interneuron origin of schizophrenia pathophysiology. Neuropharmacology 62, 1574–1583.CrossRefGoogle ScholarPubMed
Nejad, AB, Ebdrup, BH, Siebner, HR, Rasmussen, H, Aggernæs, B, Glenthøj, BY et al. (2011) Impaired temporoparietal deactivation with working memory load in antipsychotic-naïve patients with first-episode schizophrenia. World Journal of Biological Psychiatry 12, 271–281.CrossRefGoogle ScholarPubMed
Northoff, G (2014) Are auditory hallucinations related to the brain's resting state activity? A ‘neurophenomenal resting state hypothesis’. Clinical Psychopharmacology Neuroscience 12, 189–195.CrossRefGoogle ScholarPubMed
Olivier, MR, Killian, S, Chiliza, B, Asmal, L, Schoeman, R, Oosthuizen, PP et al. (2015) Cognitive performance during the first year of treatment in first-episode schizophrenia: a case-control study. Psychological Medicine 45, 2873–2883.CrossRefGoogle ScholarPubMed
Pallant, J (2013) SPSS survival manual. Maidenhead, England: Open University Press.Google Scholar
Peña-Casanova, J (1990) Test Barcelona. Barcelona: Masson.Google Scholar
Peralta, V and Cuesta, MJ (1994) Psychometric properties of the positive and negative syndrome scale (PANSS) in schizophrenia. Psychiatry Research 53, 31–40.CrossRefGoogle Scholar
Potkin, SG, Fleming, K, Jin, Y and Gulasekaram, B (2001) Clozapine enhances neurocognition and clinical symptomatology more than standard neuroleptics. Journal of Clinical Psychopharmacology 21, 479–483.CrossRefGoogle ScholarPubMed
Rehse, M, Bartolovic, M, Baum, K, Richter, D, Weisbrod, M and Roesch-Ely, D (2016) Influence of antipsychotic and anticholinergic loads on cognitive functions in patients with schizophrenia. Schizophrenia Research and Treatment 2016, 8213165.CrossRefGoogle ScholarPubMed
Reitan, R and Wolfson, D (1993) The Halstead-Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation. Tucson, AZ: Neuropsychology Press.Google Scholar
Ribeiz, SR, Bassitt, DP, Arrais, JA, Avila, R, Steffens, DC and Bottino, CM (2010) Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature. CNS Drugs 24, 303–317.CrossRefGoogle Scholar
Risbrough, V, Bontempi, B and Menzaghi, F (2002) Selective immunolesioning of the basal forebrain cholinergic neurons in rats: effect on attention using the 5-choice serial reaction time task. Psychopharmacology 164, 71–81.CrossRefGoogle ScholarPubMed
Roegge, CS, Perraut, C, Hao, X and Levin, ED (2007) Histamine H1 receptor involvement in prepulse inhibition and memory function: relevance for the antipsychotic actions of clozapine. Pharmacology, Biochemistry and Behavior 86, 686–692.CrossRefGoogle ScholarPubMed
Rudolph, JL, Salow, MJ, Angelini, MC and McGlinchey, RE (2008) The anticholinergic risk scale and anticholinergic adverse effects in older persons. Archives of Internal Medicine 168, 508–513.CrossRefGoogle ScholarPubMed
Sarter, M, Hasselmo, ME, Bruno, JP and Givens, B (2005) Unraveling the attentional functions of cortical cholinergic inputs: interactions between signal-driven and cognitive modulation of signal detection. Brain Research. Brain Research Reviews 48, 98–111.CrossRefGoogle ScholarPubMed
Seidman, LJ, Buka, SL, Goldstein, JM and Tsuang, MT (2006) Intellectual decline in schizophrenia: evidence from a prospective birth cohort 28 year follow-up study. Journal of Clinical and Experimental Neuropsychology 28, 225–242.CrossRefGoogle ScholarPubMed
Silvestri, S, Seeman, MV, Negrete, JC, Houle, S, Shammi, CM, Remington, GJ et al. (2000) Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology 152, 174–180.CrossRefGoogle ScholarPubMed
Takeuchi, H, Suzuki, T, Remington, G, Bies, RR, Abe, T, Graff-Guerrero, A et al. (2013) Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study. Schizophrenia Bulletin 39, 993–998.CrossRefGoogle ScholarPubMed
Trampush, JW, Lencz, T, DeRosse, P, John, M, Gallego, JA, Petrides, G et al. (2015) Relationship of cognition to clinical response in first-episode schizophrenia spectrum disorders. Schizophrenia Bulletin 41, 1237–1247.CrossRefGoogle ScholarPubMed
Vinogradov, S, Fisher, M, Warm, H, Holland, C, Kirshner, MA and Pollock, BG (2009) The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia. American Journal of Psychiatry 166, 1055–1062.CrossRefGoogle Scholar
Vita, A, De Peri, L, Deste, G, Barlati, S and Sacchetti, E (2015) The effect of antipsychotic treatment on cortical gray matter changes in schizophrenia: does the class matter? A meta-analysis and meta-regression of longitudinal magnetic resonance imaging studies. Biological Psychiatry 78, 403–412.CrossRefGoogle Scholar
Wechsler, D (1999) Wechsler Adult Intelligence Scale III. Madrid: TEA ediciones.Google Scholar
Weickert, TW, Goldberg, TE, Marenco, S, Bigelow, LB, Egan, MF and Weinberger, DR (2003) Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia: critical examination of confounds. Neuropsychopharmacology 28, 1491–1500.CrossRefGoogle ScholarPubMed
Wu, JQ, Chen da, C, Tan, YL, Xiu, MH, Yang, FD, Soares, JC et al. (2016) Cognitive impairments in first-episode drug-naive and chronic medicated schizophrenia: MATRICS consensus cognitive battery in a Chinese Han population. Psychiatry Research 238, 196–202.CrossRefGoogle Scholar
Supplementary material: File

Ballesteros et al. supplementary material 1

Appendix

Download Ballesteros et al. supplementary material 1(File)
File 18 KB
26
Cited by

Save article to Kindle

To save this article to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Is cognitive impairment associated with antipsychotic dose and anticholinergic equivalent loads in first-episode psychosis?
Available formats
×

Save article to Dropbox

To save this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you used this feature, you will be asked to authorise Cambridge Core to connect with your Dropbox account. Find out more about saving content to Dropbox.

Is cognitive impairment associated with antipsychotic dose and anticholinergic equivalent loads in first-episode psychosis?
Available formats
×

Save article to Google Drive

To save this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you used this feature, you will be asked to authorise Cambridge Core to connect with your Google Drive account. Find out more about saving content to Google Drive.

Is cognitive impairment associated with antipsychotic dose and anticholinergic equivalent loads in first-episode psychosis?
Available formats
×
×

Reply to: Submit a response

Please enter your response.

Your details

Please enter a valid email address.

Conflicting interests

Do you have any conflicting interests? *